chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types

Clicks: 192
ID: 184405
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #576 of 644 articles by views in sudebno-meditsinskaia ekspertiza

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 644 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Overexpression of the chondroitin sulfate proteoglycan 4 (CSPG4) has been associated with the pathology of multiple types of such as melanoma, breast cancer, squamous cell carcinoma, mesothelioma, neuroblastoma, adult and pediatric sarcomas, and some hematological cancers. CSPG4 has been reported to exhibit a role in the growth and survival as well as in the spreading and metastasis of tumor cells. CSPG4 is overexpressed in several malignant diseases, while it is thought to have restricted and low expression in normal tissues. Thus, CSPG4 has become the target of numerous anticancer treatment approaches, including monoclonal antibody-based therapies. This study reviews key potential anti-CSPG4 antibody and immune-based therapies and examines their direct antiproliferative/metastatic and immune activating mechanisms of action.
Reference Key
ilieva2018frontierschondroitin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Kristina M. Ilieva;Kristina M. Ilieva;Anthony Cheung;Anthony Cheung;Silvia Mele;Giulia Chiaruttini;Silvia Crescioli;Merope Griffin;Mano Nakamura;Mano Nakamura;James F. Spicer;Sophia Tsoka;Katie E. Lacy;Andrew N. J. Tutt;Andrew N. J. Tutt;Sophia N. Karagiannis;Sophia N. Karagiannis
Journal sudebno-meditsinskaia ekspertiza
Year 2018
DOI
10.3389/fimmu.2017.01911
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.